Exploring the Association between Sweet Liking and Treatment Response to Naltrexone in Patients with Alcohol Use Disorder [0.03%]
探究甜食喜好与酒精使用障碍患者纳曲酮治疗反应之间的关系
Min-Chiao Chang,Chun-Hsin Chen,Shih-Chun Meng et al.
Min-Chiao Chang et al.
Background: Response to naltrexone varies among individuals with alcohol use disorder (AUD). Studies in Western populations have linked the sweet-liking (SL) phenotype, reflecting an individual's hedonic response to sweet...
Auricular Transcutaneous Vagus Nerve Stimulation Stabilizes Event Segmentation Through Modulation of Working Memory Representations [0.03%]
耳部经皮迷走神经刺激通过调节工作记忆表征稳定事件分段
Xianzhen Zhou,Foroogh Ghorbani,Veit Roessner et al.
Xianzhen Zhou et al.
Background: Segmenting continuous experience into discrete units-event segmentation-is fundamental for situational awareness and adaptive action. Based on Event Segmentation Theory (EST), we used auricular transcutaneous ...
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report [0.03%]
迷走神经刺激治疗难治性抑郁症疗效的长期性——来自RECOVER试验的结果报告
Charles R Conway,Augustus John Rush,Scott T Aaronson et al.
Charles R Conway et al.
Importance: Greater levels of treatment resistance in major depressive disorder (MDD) are associated with lower rates of initial benefit and higher rates of relapse (lower durability). ...
Randomized Controlled Trial
The international journal of neuropsychopharmacology. 2026 Jan 6;29(1):pyaf080. DOI:10.1093/ijnp/pyaf080 2026
Pharmacokinetic and pharmacodynamic results from a randomized controlled study with the GHSR blocker PF-5190457 in recently abstinent patients with alcohol use disorder [0.03%]
PF-5190457（一种GHSR阻断剂）在最近停止饮酒的酒精使用障碍患者中的药代动力学和药效学结果：一项随机对照研究
Ryan E Tyler,Rabea K Pfaff,R M Naseer Khan et al.
Ryan E Tyler et al.
Objective: Ghrelin and LEAP2 act via the growth hormone secretagogue receptor (GHSR), which modulates feeding, alcohol use, and endocrine and immune system function. The GHSR blocker PF-5190457 has potential as a novel ph...
Diazepam modulates anterior cingulate glutamate levels in people at clinical high-risk for psychosis [0.03%]
地西泮调节临床高危人群前扣带回谷氨酸水平
Amanda Kiemes,Nicholas R Livingston,Paulina B Lukow et al.
Amanda Kiemes et al.
Background: Preclinical evidence suggests that modulating neural excitation through diazepam administration, a positive allosteric modulator of GABAA receptors, can prevent the emergence of behavioral and neurobiological ...
Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant [0.03%]
失眠症当前和新型双重食欲素受体拮抗剂：VOR 临床试验的新进展
Yukihiro Chino,Hiroyuki Sugiyama,Shigeyuki Chaki et al.
Yukihiro Chino et al.
Insomnia is a serious public health concern. As the widely prescribed hypnotics that positively modulate gamma-aminobutyric acid (GABA)A receptor activity have various safety concerns, there is a growing demand for the development of novel ...
Partial agonist antipsychotic drugs differentially interact with a secondary binding site at the dopamine D2 receptor [0.03%]
部分激动剂抗精神病药物通过与多巴胺D2受体的二级结合位点不同地相互作用而产生不同的药理作用
Richard Ågren,Kristoffer Sahlholm
Richard Ågren
Adjunctive brexpiprazole in patients with major depressive disorder who show minimal or partial response to antidepressant treatment: post hoc analysis of randomized controlled trials [0.03%]
在对现有抗抑郁治疗反应不佳的抑郁症患者中研究brexpiprazole附加疗法：随机对照试验的事后分析
Shivani Kapadia,Zhen Zhang,Ferhat Ardic et al.
Shivani Kapadia et al.
Importance: Many patients with major depressive disorder (MDD) have 0% to
Modulatory effects of GLT-1 enhancer, MC-100093, on glutamate uptake and associated signaling pathways in female and male alcohol preferring rats exposed to ethanol [0.03%]
GLT-1增强剂MC-100093调节酒精成瘾大鼠的谷氨酸摄取及相关信号通路的作用机制研究
Ahmed Alotaibi,Khokon Kanti Bhowmik,Woonyen Wong et al.
Ahmed Alotaibi et al.
Background: Ethanol consumption disrupts glutamate homeostasis in several brain regions. The uptake of extracellular glutamate is regulated in the majority by the astrocytic glutamate transporter 1 (GLT-1), and cystine-gl...
Methodological Considerations for Interpreting Ketamine-Naltrexone Trials in Depression [0.03%]
解读抑郁症酮氯普马试验的方法学考量
Igor D Bandeira,Luke A Jelen,Jason M Tucciarone et al.
Igor D Bandeira et al.